Response to ‘‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature?’ by Scherlinger et al

Published on Jan 23, 2019in Annals of the Rheumatic Diseases14.299
· DOI :10.1136/annrheumdis-2018-214952
B. Glintborg7
Estimated H-index: 7
(Copenhagen University Hospital),
Anne Loft32
Estimated H-index: 32
(AU: Aarhus University)
+ 21 AuthorsMerete Lund Hetland44
Estimated H-index: 44
(UCPH: University of Copenhagen)
Thank you for the interest1 in our recent publication, in which we explored treatment outcomes following a Danish mandatory switch from originator to biosimilar etanercept (SB4, 50 mg) in routine care.2 We showed that of the 2061 patients who were receiving originator etanercept and thus were eligible for the switch, as many as four of five (79%) switched to the biosimilar, despite the continued availability of the originator drug (as 25 mg pen or 50 mg powder solution). Among the patients who switched, we observed high retention rates of the biosimilar. The 6-month …
  • References (5)
  • Citations (1)
📖 Papers frequently viewed together
3 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
3 CitationsSource
#1Marc Scherlinger (University of Bordeaux)H-Index: 6
#2Emmanuel Langlois (University of Bordeaux)H-Index: 2
Last. Thierry Schaeverbeke (University of Bordeaux)H-Index: 12
view all 4 authors...
Abstract Objective To study acceptance rate and factors influencing acceptance of the switch from originator etanercept (Enbrel©) to biosimilar etanercept (SB4, Benepali©) in patients with rheumatic disease. Methods Patients with a well-controlled rheumatic disease consulting in our rheumatology department were offered the switch for SB4. After oral and written information concerning biosimilar, free choice to accept the switch was left to the patients. The main outcome was primary switch accept...
12 CitationsSource
#1Bente Glintborg (Gentofte Hospital)H-Index: 12
#2Anne Loft (AU: Aarhus University)H-Index: 32
Last. Merete Lund Hetland (UCPH: University of Copenhagen)H-Index: 44
view all 24 authors...
Objectives Real-world evidence on effectiveness of switching to biosimila r etanercept is scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) to biosimilar (SB4) etanercept was issued for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) in 2016. Clinical characteristics and treatment outcomes were studied in ETA-treated patients, who switched to SB4 (switchers) or maintained ETA (non-switchers). Retentio...
23 CitationsSource
#1L TweehuysenH-Index: 6
#2V.J.B. HuiskesH-Index: 2
Last. A.A. den Broeder (Radboud University Nijmegen)H-Index: 32
view all 8 authors...
22 CitationsSource
#1B. Glintborg (Copenhagen University Hospital)H-Index: 7
#2Jan Sørensen (RCSI: Royal College of Surgeons in Ireland)H-Index: 25
Last. Merete Lund Hetland (UCPH: University of Copenhagen)H-Index: 44
view all 3 authors...
Objectives National Danish guidelines in May 2015 dictated a mandatory switch from originator infliximab (INX) to biosimilar CT-P13 in patients with inflammatory rheumatic disease. We investigated if this non-medical switch changed use of outpatient hospital resources. Methods Observational cohort study. Switchers were identified in DANBIO. Rheumatic outpatient contacts, visits and services were identified in the National Patient Registry. The 6-month rate for (1) number of visits (or services) ...
5 CitationsSource
Cited By1
#1Josef S. Smolen (University of Vienna)H-Index: 114
#2João Gonçalves (University of Lisbon)H-Index: 35
Last. Jake Yongkwon Lee (Samsung)H-Index: 1
view all 5 authors...
Compared with the original approved biological drug on which it is based, a biosimilar has highly similar physicochemical characteristics and biological activity, as well as equivalent efficacy and no clinically meaningful differences in safety and immunogenicity. Before they are approved, biosimilars must undergo a rigorous development process using state-of-the-art technologies to establish biosimilarity to the reference biological product. After approval, biosimilars must comply with good pha...
2 CitationsSource